Results 141 to 150 of about 516,620 (290)

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

Discovery and development of a bispecific antibody for the treatment of hemophilia. [PDF]

Proc Natl Acad Sci U S A
Pao W.
europepmc   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors. [PDF]

J Hematol Oncol
Lou J, Lyu Y.
europepmc   +1 more source

Spatial Atlas of Small Cell Lung Carcinoma Reveals Intratumoral Tumor‐State Heterogeneity and an MMP12+ Macrophage Niche

Cancer Science, EarlyView.
Spatial transcriptomic profiling of SCLC revealed marked intratumoral heterogeneity, including coexisting neuroendocrine and non‐neuroendocrine states and spatially heterogeneous hypoxia, and identified an MMP12+ macrophage population enriched at hypoxic and necrotic tumor interfaces.
Naozane Nomura, Naoe Jimbo, Takaaki Nakanishi, Yukinobu Ito, Maki Sakaguchi, Daichi Maeda, Hiroko Ikeda, Tsukasa Ueda, Hayato Koba, Seiji Yano, Isao Matsumoto, Patrick Micke, Takayuki Kodama, Manabu Shigeoka, Yu‐ichiro Koma, Masafumi Horie   +15 more
wiley   +1 more source

Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide-HLA complex. [PDF]

MAbs
Watkins-Yoon J, Lu WC, Petrunak EM, Tubo NJ, Halmos S, McConaughy W, Ciuffa R, Weber C, Friedensohn S, Justesen S, Skovgaard M, Rachel R, Goshert C, Liu L, Bobrowicz P, Molldrem JJ, Zha D.   +16 more
europepmc   +1 more source

Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.

, 1991
Bispecific antibodies with specificity for the CD3/TCR complex of CTL and a target cell Ag can bridge both cell types and trigger cellular cytoxicity.
Brissinck, J, Demanet, Christian, Leo, Oberdan, Thielemans, Kris, Moser, Muriel   +4 more
core  

Near pan-alphavirus neutralization by an antibody-nanobody bispecific. [PDF]

MAbs
Pletnev S, Gardner CL, Sutton MS, Zhang B, Callahan V, Green C, Morano NC, Bylund T, Dunagan MM, Tsybovsky Y, Goldman ER, Shapiro L, Burke CW, Fox JM, Roederer M, Kwong PD, Zhou T.   +16 more
europepmc   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa share Lasker Award honors for revolutionary hemophilia A therapy. [PDF]

J Clin Invest
Flaumenhaft R.
europepmc   +1 more source